IL1B rs16947: Promoter Variant and Inflammation Research
The rs16947 polymorphism is a promoter variant located upstream of the IL1B gene, which encodes the critical pro-inflammatory cytokine interleukin-1 beta. Widely evaluated in immunogenetics literature alongside its linked promoter loci, the variant has been investigated for its potential regulatory influence on cytokine transcription and chronic inflammatory states. Current clinical and epidemiological evidence linking rs16947 to specific disease risks remains limited, demonstrating modest statistical associations rather than direct causation.
What each genotype means
Typical baseline expression
You carry two copies of the C allele for this IL1B promoter variant. In published research, this genotype is generally associated with standard baseline interleukin-1 beta expression, though some studies report mixed or context-specific findings across different inflammatory markers. These findings reflect statistical observations from population studies and do not diagnose any health condition.
Carried by roughly 40% to 50% of individuals of European ancestry and about 25% to 30% of East Asian populations.
Intermediate inflammatory marker profile
You carry one copy of the C allele and one copy of the T allele. Genetic research indicates that heterozygous carriers show intermediate promoter activity and variable cytokine levels depending on environmental exposures and tissue type. Because findings across ethnic groups and disease studies are inconsistent, this genotype represents only a modest statistical association rather than a certain health outcome.
Carried by approximately 40% to 50% of individuals across both European and East Asian populations.
Altered cytokine response profile
You carry two copies of the T allele, which literature often designates as the variant allele at promoter position -511. Some association studies link this genotype to altered or heightened interleukin-1 beta transcriptional activity and differences in inflammatory responses, although findings remain mixed and vary significantly between ancestral groups. This profile does not indicate an inflammatory disorder or serve as medical advice.
Carried by about 10% to 15% of people of European descent and roughly 20% to 25% of individuals of East Asian ancestry.
Genomic Context and Molecular Characteristics
The single nucleotide polymorphism rs16947 is situated in the 5' regulatory promoter region of the interleukin 1 beta (IL1B) gene on chromosome 2. In historical biomedical literature and candidate-gene reports, promoter polymorphisms in this locus are frequently designated by their relative distance from transcription or translation start sites, such as c.-511C>T or c.-598C>T depending on the transcript isoform referenced. Because it resides within a regulatory sequence rather than an exon, rs16947 does not alter the amino acid structure of the resulting protein. Instead, variants in this promoter region are primarily studied for their potential to alter transcription factor binding motifs, which can subtly modulate the baseline or stimulus-induced transcription rates of IL1B mRNA in response to physiological triggers.
The Biological Role of the IL1B Gene
The IL1B gene encodes interleukin-1 beta (IL-1β), a potent pro-inflammatory cytokine produced predominantly by activated immune cells such as monocytes and macrophages. IL-1β is initially synthesized as an inactive precursor known as pro-IL-1β, which requires enzymatic cleavage by caspase-1 within the inflammasome complex to achieve its active, secreted form. Once released, IL-1β plays a fundamental role in orchestrating immune responses, coordinating leukocyte recruitment, inducing secondary inflammatory mediators like interleukin-6, and initiating systemic responses such as fever. Because unchecked IL-1β signaling can lead to tissue damage and systemic inflammation, the body tightly regulates its expression, maturation, and competitive receptor binding via natural antagonists.
State of the Evidence: Inflammatory Traits and Complex Conditions
A substantial body of candidate-gene association studies has explored whether promoter variations within IL1B, including rs16947 and tightly linked loci like rs16944, predispose individuals to chronic inflammatory conditions, autoimmune disorders, periodontal disease, or altered susceptibility to infectious pathogens. However, the overall strength of evidence is classified as limited. Findings across independent cohorts and diverse ancestries are frequently mixed, with some studies identifying modest risk modifications while others report no statistically significant association. Discrepancies often stem from small cohort sizes, population-specific linkage disequilibrium, and gene-environment interactions. Larger genome-wide association studies (GWAS) have generally failed to identify rs16947 as a standalone, major driver of complex polygenic phenotypes.
Population Genetics and Linkage Disequilibrium
Allele distributions for rs16947 vary significantly across global biogeographical ancestral groups. In European populations, the minor allele frequency typically ranges between approximately 30% and 35%, whereas in East Asian populations, it is much more frequent, reaching approximately 45% to 50%. In genomic analysis, rs16947 often exists in moderate to strong linkage disequilibrium with other nearby regulatory markers within the interleukin-1 gene cluster on chromosome 2. This close genomic proximity means that individual alleles are frequently inherited together as multi-variant haplotypes, making it challenging for observational studies to isolate the distinct functional contribution of rs16947 from surrounding genetic variants.
Clinical Interpretation and Limitations
It is essential to distinguish between observational population associations and clinical diagnostic tools. The rs16947 variant is not a diagnostic marker, and possessing one or two copies of an associated allele does not mean an individual will develop any inflammatory disease or abnormal cytokine profile. Similarly, while research literature investigates regulatory variants for potential downstream pharmacodynamic effects or cytokine regulation, rs16947 is not an established clinical pharmacogenomic marker with CPIC dosing recommendations. Any genotype at this locus should be understood as a minor biological component within a vastly complex immune network heavily shaped by lifestyle, environment, and overall polygenic background.
How common is this variant?
The minor allele frequency for rs16947 is approximately 0.30 to 0.35 in European populations and reaches approximately 0.45 to 0.50 in East Asian populations, demonstrating notable variation across global ancestries.
Frequently asked questions
What is the rs16947 variant in the IL1B gene?
The rs16947 variant is a single nucleotide polymorphism located in the non-coding promoter region upstream of the IL1B gene. It has been studied by researchers to evaluate whether subtle changes in promoter sequence influence how much interleukin-1 beta protein an immune cell produces.
Does having the rs16947 T allele mean I have chronic inflammation?
No, having the T allele does not mean you have or will develop chronic inflammation. The evidence linking this variant to elevated cytokine levels or clinical disease is limited and variable across human populations, meaning lifestyle and overall health have far greater influence.
Can my rs16947 genotype guide my medication or medical treatments?
No, rs16947 is not an actionable clinical pharmacogenomic marker and cannot be used to select or adjust medications. You should always discuss any medication choices, potential dosing adjustments, or medical treatments directly with your doctor or pharmacist.
Why do scientific studies report contradictory results for rs16947?
Many candidate-gene studies for rs16947 were relatively small and examined populations with differing ancestral backgrounds and environmental exposures. Because immune responses involve hundreds of genes interacting with external factors, small individual genetic effects often vary widely between different research cohorts.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16947?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IL1B
This SNP is recognized as a modifier of inflammatory response, potentially affecting responses to anti-TNF therapies.
Promoter single nucleotide polymorphism influencing baseline inducible interleukin-1 beta transcriptional activity and inflammatory response phenotypes.
Interleukin-1 beta variant associated with systemic inflammatory markers and potential modulation of dietary response.
Promoter regulatory single-nucleotide variant in interleukin-1 beta associated with altered inflammatory cytokine secretion and chronic inflammation predisposition.
This variant is associated with altered cytokine production and susceptibility to inflammatory conditions.
This polymorphism in the interleukin-1 beta gene has been studied for its role in the pharmacogenomics of apremilast response in patients with psoriasis.